SynthesisBritish journal of cancer2007
Meta-analysis of clodronate and breast cancer survival.
Synthesis in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Pooled it
- SEOM guidelines for the treatment of bone metastases from solid tumours.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012Guideline
- NCCN Task Force Report: Bone Health in Cancer Care.Journal of the National Comprehensive Cancer Network : JNCCN · 2009Guideline
- An open cohort study of bone metastasis incidence following surgery in breast cancer patients.BMC cancer · 2010Trial
- Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes.Frontiers in immunology · 2021Review
- The Biology of Bone Metastasis.Cold Spring Harbor perspectives in medicine · 2018Review
- Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.Current treatment options in oncology · 2018Review
- Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.Journal of bone oncology · 2017Review
- Article
- Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.The oncologist · 2014Article
- Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives.Journal of clinical medicine · 2014Review
- The anti-tumour effects of zoledronic acid.Journal of bone oncology · 2014Review
- Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.Journal of clinical medicine · 2014Review
- Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!Journal of thoracic disease · 2013Article
- Optimal management of bone metastases in breast cancer patients.Breast cancer (Dove Medical Press) · 2011Review
- Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer.Breast cancer (Dove Medical Press) · 2011Review
- Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.Clinical breast cancer · 2010Article
- Metastasis and bone loss: advancing treatment and prevention.Cancer treatment reviews · 2010Review
- Future directions of bone-targeted therapy for metastatic breast cancer.Nature reviews. Clinical oncology · 2010Review
- [Bisphosphonates in adjuvant therapy of breast cancer].Medizinische Klinik (Munich, Germany : 1983) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical trials have reported conflicting results on whether oral clodronate therapy improves survival in breast cancer patients. This study was undertaken to evaluate further the effect of oral clodronate therapy on overall survival, bone metastasis-free survival and nonskeletal metastasis-free survival among breast cancer patients. An extensive literature search was undertaken for the period 1966 to July 2006 to identify clinical trials examining survival in breast cancer patients who received 2 or 3 years of oral clodronate therapy at 1600 mg day(-1) compared with those without therapy. Meta-analyses were carried out separately for patients diagnosed with advanced breast cancer and early breast cancer. Our meta-analysis found no evidence of any statistically significant difference in overall survival, bone metastasis-free survival or nonskeletal metastasis-free survival in advanced breast cancer patients receiving clodronate therapy or early breast cancer patients receiving adjuvant clodronate treatment compared with those who did not receive any active treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.